Ignite Creation Date:
2024-05-06 @ 9:19 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02957019
Status:
TERMINATED
Last Update Posted:
2023-10-10
First Post:
2016-10-27
Brief Title:
A Phase III Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma DLBCL
Sponsor:
Philogen SpA
Organization:
Philogen SpA
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-07-31
Start Date Type:
ACTUAL
Primary Completion Date:
2023-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-29
Completion Date Type:
ACTUAL
First Submit Date:
2016-10-27
First Submit QC Date:
November 3 2016
Study First Post Date:
2016-11-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-06
Last Update Post Date:
2023-10-10
Last Update Post Date Type:
ACTUAL